biotech compani overus whole
public relat effort mechan get stock
price say peter drake biotech analyst
chicago-bas vector secur
instanc isi pharmaceut announc press
releas last week receiv approv u.
food drug administr begin phase clinic
trial compani stock climb 13 5/8 12 3/4
day
enter phase trial approv process
say sarah gordon biotech analyst new
york-bas amerindo invest advisor inde fda
spurn compani applic within 30 day
biotech compani begin test applic
turn
isi spokesman say matter boil
semant debat add compani believ
applic dealt fda routin way
isi got fda phone call clear trial
21 day
biotech compani one tout
press releas cours biotech stock
market hottest perform recent mani
biotech stock sell lofti price despit lack
earn
torrent often-mislead press releas
biotech compani possibl fda approv
process rigor world averag take
12 year $ 231 million get one new medicin
laboratori pharmaci accord tuft univers
studi yet fda approv sale one 4,000
compound test peopl
fda adher strict polici confidenti
agenc wo ever public disclos progress
review drug yet fda bar biotech compani
say whatev wish review process
220 public trade biotech compani
competit gain recognit financ
stock market fierc easi understand
talk analyst investor compani might want
hype drug expect fda approv
easi see compani get away hype
biotech compani need capit put best
foot forward given opportun say jeff casdin
oppenheim lead biotech analyst play
good news omit bad news compani
say someth fda wo say
whether press releas meet analyst
investor lot instanc compani
misrepres efficaci drug fda-sanct
clinic test say michael gordon portfolio manag
$ 900 million fidel select biotechnolog fund
xoma berkeley calif. biotech compani face sever
investor lawsuit feder court san francisco
compani issu press releas april 1990.
month compani got letter fda tell xoma
data submit e5 drug treat septic
shock syndrom suffici approv
product
fda cite lack convinc preclin
protect studi anim margin
best efficaci data man say lehman brother analyst
teena lerner serious setback compani
yet xoma report problem public
august 1990 quarter report downplay fda
letter xoma simpli said fda ask addit
inform includ data clinic trial
previous conduct letter came light
juli 1991 thank wide watch patent-infring
trial involv xoma centocor
despit letter seri press releas analyst
meet investor confer xoma confid pitch
drug without refer fda request xoma say
done anyth wrong defend
suit feel strong made full disclosur
gone press releas regulatori file
public statement xoma spokeswoman say
oppenheim mr. casdin disagre xoma kept public
dark year say
even xoma come attack alleg
mislead investor chief competitor centocor also
hot water investor last month press
releas centocor releas routin result fourth
quarter buri deep sixth paragraph
releas appear investor terribl news
fda rais addit issu centocor septic
shock drug centocor believ resolv
satisfactorili releas read centocor said
releas could materi advers effect
concern
centocor issu 30 press releas last
year declin elabor announc
admiss left investor hunger addit
inform centocor issu press releas everi time one
monoclon antibodi belch complain richard
bock veteran biotech stockbrok sutro co.
problem fda stop
releas anyth time everyon want know
someth
centocor spokesman say centocor put press
releas appropri add anyon
believ antibodi belch might question
scientif compet
compani live promis earlier
press releas alway blame delay
fda-rel problem tactic virtual foolproof
agenc wo set investor straight
research industri recent last year
compani attribut delay fda review herpid
antivir drug extraordinari aidsrel polit
pressur fda compani sought approv drug
1988
last month compani told investor approv
test anoth product heparin remov devic
system would like take longer expect
recent environ devic side fda
result breast heart-valv implant
research stockhold scratch head note
especi recent case research
submit data fda would even allow begin
test peopl gari crocker compani chairman deni
blame fda delay think notic
compani fda general get back peopl
slower document submit say
bonni perkin analyst follow compani
william blair co. say despit delay remain
bullish research industri critic
put mani press releas 25 last year
compani seem respond declin share
price issu press releas
organogenesi cambridg mass. compani develop
living-tissu equival appear one
jan. 30 tuesday organogenesi issu eight differ
releas almost mani issu entir
preced year releas hail everyth
groundbreak new corpor headquart research
paper confer maui hawaii
barrag releas began soon organogenesi
stock rose 25 7/8 mid-januari quick fell
back yesterday organogenesi close 13 7/8 one case
compani public data present medic
confer three week earlier
organogenesi spokeswoman wo say compani
wait long issu releas say
organogenesi releas anyth
stock price
